Completed PHASE2 INTERVENTIONAL 4-arm NCT00454636

A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.

Open Label, Phase II Study of Capecitabine (Xeloda®) as Fluoropyrimidine of Choice in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer Suitable for Treatment With a Fluoropyrimidine-Based Regimen

Sponsor: Hoffmann-La Roche

Conditions Gastric Cancer

Interventions Capecitabine Cisplatin Docetaxel Epirubicin Oxaliplatin

Updated 6 times since 2017 Last updated: Aug 23, 2016 Started: Mar 31, 2007 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Gastric Cancer, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Alcorcón, Spain , Alcoy, Spain , Barbastro, Spain , Barcelona, Spain , Bilbao, Spain , Burgos, Spain , Cadiz, Spain , Castellon, Spain , Córdoba, Spain and 31 more locations